The esophageal dose–volume parameters for predicting Grade I–II acute esophagitis correlated with weight loss and serum albumin decrease in lung cancer radiotherapy

Kaymak, Zümrüt Arda; Özkan, Emine Elif; Özseven, Alper

doi:10.4103/jcrt.jcrt_410_19

Cited by 6 publications

(5 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Opioids alleviate pain and reduce inflammation, improving immunotherapy efficacy. Lastly, the body’s ALB level reflects the patient’s nutritional status and indicates the patient’s liver function reserve and treatment tolerance [ 39 , 40 ]. Therefore, considering systemic inflammation and ALB levels aids understanding of the immune response.…”

Section: Discussionmentioning

confidence: 99%

Prognostic value of systemic immune-inflammation index/albumin ratio for immunotherapy-treated patients receiving opioids

Yan,

Kang,

Cao

et al. 2024

PLoS ONE

View full text Add to dashboard Cite

Objective This study evaluated the effect of the systemic immune-inflammation index/albumin ratio (SII/ALB) on the prognosis of immunotherapy-treated patients receiving opioids. Methods A retrospective analysis was conducted of 185 immunotherapy-treated patients who received opioids at Xuzhou Central Hospital from 01/09/2021 to 01/09/2023. The results of related clinical data were collected during the week before the cancer patients received immunotherapy. The SII/ALB cut-off value was determined, and the relationship between the SII/ALB and clinical pathological parameters was analyzed using the chi-square test. The effect of the SII/ALB on progression-free survival (PFS) was examined using Kaplan-Meier curves and the Cox proportional hazard model. Result The SII/ALB cut-off value was 20.86, and patients were divided into low (SII/ALB ≤ 20.86) and high (SII/ALB > 20.86) SII/ALB groups. Adverse reactions (hazard ratio [HR] = 0.108; 95% confidence interval [CI]: 0.061–0.192, P < 0.001) and the SII/ALB (HR = 0.093; 95% CI: 0.057–0.151, P < 0.001) were independent prognostic factors for PFS. Compared with the high SII/ALB group, the low SII/ALB group had longer PFS after opioid treatment (12.2 vs. 5.2 months, P < 0.001). Conclusion The SII/ALB is a potentially important prognostic parameter in immunotherapy-treated patients receiving opioids.

show abstract

Section: Discussionmentioning

confidence: 99%

Prognostic value of systemic immune-inflammation index/albumin ratio for immunotherapy-treated patients receiving opioids

Yan,

Kang,

Cao

et al. 2024

PLoS ONE

View full text Add to dashboard Cite

show abstract

“…Inflammation can deplete the nutrient reserves in the body, and lead to persistent activation of immune cells and inflammatory responses, thereby inhibiting the immune response to tumors and enhancing tumor escape mechanisms (61,62). Albumin levels and weight not only reflect the nutritional status of patients, but also indicate their liver function reserve and treatment tolerance (63,64). Furthermore, 'a previous study reported that low levels of serum albumin are associated with systemic inflammation (65).…”

Section: Discussionmentioning

confidence: 99%

Prognostic value of nutritional and inflammatory markers in patients with hepatocellular carcinoma who receive immune checkpoint inhibitors

Liu,

Zhao,

Zhang

et al. 2023

Oncol Lett

View full text Add to dashboard Cite

The emergence of immune checkpoint inhibitors (ICIs) has provided a new treatment option for patients with hepatocellular carcinoma (HCC). However, further evaluation is needed for determining biomarkers for the use of ICIs. The present study evaluated the prognostic value of certain nutritional and inflammatory markers in patients with HCC who received ICIs. In the present study, the clinical data of 151 patients with HCC who received ICIs at Harbin Medical University Cancer Hospital from January 2019 to December 2021 were collected. The blood parameters of all patients before treatment were collected to evaluate certain nutritional and inflammatory markers, including the prognostic nutrition index (PNI), nutritional risk index (NRI), geriatric NRI (GNRI), systemic immune-inflammation index (SII), systemic inflammation response index (SIRI) and advanced lung cancer inflammation index (ALI). Patients were grouped using the cut-off value calculated using receiver operating characteristic (ROC) curves, and the relationship between these biomarkers and prognosis was evaluated through survival analysis. Furthermore, the prognostic value of these biomarkers was assessed through multivariate Cox regression analysis and construction of nomograms. Finally, time-ROC curves were plotted to compare the differences in predicting prognosis between the biomarkers. In the preliminary survival analysis, all inflammatory and nutritional markers included in the present study were significantly associated with the prognosis of HCC in patients who received ICIs. Similar results were obtained in a subgroup analysis of patients with different Barcelona Clinic Liver Cancer (BCLC) stages. Multivariate Cox regression analysis demonstrated that GNRI, PNI, BCLC stage and Tumor-Node-Metastasis (TNM) stage were significantly associated with progression-free survival (PFS), whereas GNRI, BCLC stage and TNM stage were also significantly associated with overall survival (OS). Furthermore, the time-ROC curves indicated that nutritional indicators had a higher prognostic value in all indexes, especially GNRI. The C-index (95% confidence interval) of the nomograms for predicting the survival probability of patients who received ICIs were 0.801 (0.746-0.877) and 0.823 (0.761-0.898) for PFS and overall OS, respectively, which also showed high accuracy. In conclusion, the present study demonstrated that PNI, GNRI, NRI, SII, SIRI and ALI were all related to the efficacy of ICIs in HCC and could serve as non-invasive biomarkers for ICI treatment effectiveness. Moreover, compared with inflammatory markers, nutritional markers had greater predictive ability, with GNRI being the biomarker with the best prognostic value.

show abstract

“…[ 12 ] found that Alb < 35 g/L generally represented a poor prognosis for patients with metastatic non-small cell lung cancer (mNSCLC). The level of Alb can also predict the occurrence of adverse reactions in lung cancer patients after treatment [ 13 ]. A clinical study by Kazuki et al.…”

Section: Introductionmentioning

confidence: 99%

Research progress and value of albumin-related inflammatory markers in the prognosis of non-small cell lung cancer: a review of clinical evidence

et al. 2023

View full text Add to dashboard Cite

Inflammatory markers have a wide range of predictive values in the prognosis of non-small lung cancer (NSCLC). Poor nutritional status usually means a poor prognosis in patients with NSCLC, which is widely recognized by oncologists and nutritionists. Serum albumin has a certain value in evaluating the prognosis of patients. Several inflammatory albumin-related markers have been proposed, but they have not been widely used in predicting the prognosis of NSCLC in clinical practice. We aim to systematically review the published clinical evidence of albumin-related inflammatory markers in predicting the prognosis of NSCLC and to describe their progress and value. The results showed that the markers included in the review could be prognostic indicators in patients with NSCLC. However, we found that the cut-off value of albumin-related inflammatory markers with quantitative nature was very chaotic and needed to be defined by recognized standards. We summarized and compared the advantages and disadvantages of these markers, but a prospective cohort study with long-term follow-up after adjustment for important confounders is still necessary. Whether the results and conclusions could be directly applied in clinical practice needs to be identified and evaluated. There is an urgent need to classify and standardize the albumin-related inflammatory markers that play an important role in the prognosis of NSCLC, which is the key to ensuring the transformation from clinical study to clinical application.

show abstract

The esophageal dose–volume parameters for predicting Grade I–II acute esophagitis correlated with weight loss and serum albumin decrease in lung cancer radiotherapy

Cited by 6 publications

References 2 publications

Prognostic value of systemic immune-inflammation index/albumin ratio for immunotherapy-treated patients receiving opioids

Prognostic value of systemic immune-inflammation index/albumin ratio for immunotherapy-treated patients receiving opioids

Prognostic value of nutritional and inflammatory markers in patients with hepatocellular carcinoma who receive immune checkpoint inhibitors

Research progress and value of albumin-related inflammatory markers in the prognosis of non-small cell lung cancer: a review of clinical evidence

Contact Info

Product

Resources

About